|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WRAP53 |
Gene summary for WRAP53 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WRAP53 | Gene ID | 55135 |
| Gene name | WD repeat containing antisense to TP53 | |
| Gene Alias | DKCB3 | |
| Cytomap | 17p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000018 | UniProtAcc | Q9BUR4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55135 | WRAP53 | P30T-E | Human | Esophagus | ESCC | 4.35e-04 | 2.01e-01 | 0.137 |
| 55135 | WRAP53 | P31T-E | Human | Esophagus | ESCC | 4.00e-06 | 1.59e-01 | 0.1251 |
| 55135 | WRAP53 | P32T-E | Human | Esophagus | ESCC | 5.88e-12 | 2.72e-01 | 0.1666 |
| 55135 | WRAP53 | P36T-E | Human | Esophagus | ESCC | 1.35e-02 | 1.03e-01 | 0.1187 |
| 55135 | WRAP53 | P37T-E | Human | Esophagus | ESCC | 2.39e-08 | 2.18e-01 | 0.1371 |
| 55135 | WRAP53 | P39T-E | Human | Esophagus | ESCC | 5.39e-04 | 1.08e-01 | 0.0894 |
| 55135 | WRAP53 | P42T-E | Human | Esophagus | ESCC | 3.29e-08 | 1.79e-01 | 0.1175 |
| 55135 | WRAP53 | P47T-E | Human | Esophagus | ESCC | 4.22e-04 | 5.23e-02 | 0.1067 |
| 55135 | WRAP53 | P48T-E | Human | Esophagus | ESCC | 1.43e-02 | 9.27e-02 | 0.0959 |
| 55135 | WRAP53 | P49T-E | Human | Esophagus | ESCC | 5.48e-04 | 3.31e-01 | 0.1768 |
| 55135 | WRAP53 | P52T-E | Human | Esophagus | ESCC | 1.46e-08 | 1.97e-01 | 0.1555 |
| 55135 | WRAP53 | P54T-E | Human | Esophagus | ESCC | 1.23e-08 | 1.76e-01 | 0.0975 |
| 55135 | WRAP53 | P56T-E | Human | Esophagus | ESCC | 2.71e-03 | 4.00e-01 | 0.1613 |
| 55135 | WRAP53 | P57T-E | Human | Esophagus | ESCC | 4.47e-05 | 1.08e-01 | 0.0926 |
| 55135 | WRAP53 | P61T-E | Human | Esophagus | ESCC | 2.73e-04 | 1.12e-01 | 0.099 |
| 55135 | WRAP53 | P62T-E | Human | Esophagus | ESCC | 4.00e-12 | 2.11e-01 | 0.1302 |
| 55135 | WRAP53 | P65T-E | Human | Esophagus | ESCC | 4.49e-05 | 1.50e-01 | 0.0978 |
| 55135 | WRAP53 | P74T-E | Human | Esophagus | ESCC | 7.40e-16 | 4.77e-01 | 0.1479 |
| 55135 | WRAP53 | P75T-E | Human | Esophagus | ESCC | 6.09e-08 | 2.34e-01 | 0.1125 |
| 55135 | WRAP53 | P76T-E | Human | Esophagus | ESCC | 1.78e-15 | 3.14e-01 | 0.1207 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0072594110 | Esophagus | ESCC | establishment of protein localization to organelle | 311/8552 | 422/18723 | 3.02e-32 | 2.13e-29 | 311 |
| GO:0006403110 | Esophagus | ESCC | RNA localization | 166/8552 | 201/18723 | 1.95e-27 | 6.18e-25 | 166 |
| GO:003450418 | Esophagus | ESCC | protein localization to nucleus | 211/8552 | 290/18723 | 4.06e-21 | 6.60e-19 | 211 |
| GO:1903829111 | Esophagus | ESCC | positive regulation of cellular protein localization | 199/8552 | 276/18723 | 2.99e-19 | 3.45e-17 | 199 |
| GO:1904951111 | Esophagus | ESCC | positive regulation of establishment of protein localization | 216/8552 | 319/18723 | 1.01e-15 | 6.86e-14 | 216 |
| GO:005105215 | Esophagus | ESCC | regulation of DNA metabolic process | 232/8552 | 359/18723 | 2.40e-13 | 1.13e-11 | 232 |
| GO:000072319 | Esophagus | ESCC | telomere maintenance | 99/8552 | 131/18723 | 2.68e-12 | 1.08e-10 | 99 |
| GO:007189716 | Esophagus | ESCC | DNA biosynthetic process | 127/8552 | 180/18723 | 1.04e-11 | 3.85e-10 | 127 |
| GO:005105417 | Esophagus | ESCC | positive regulation of DNA metabolic process | 139/8552 | 201/18723 | 1.20e-11 | 4.33e-10 | 139 |
| GO:200057319 | Esophagus | ESCC | positive regulation of DNA biosynthetic process | 56/8552 | 66/18723 | 4.51e-11 | 1.45e-09 | 56 |
| GO:2000278110 | Esophagus | ESCC | regulation of DNA biosynthetic process | 81/8552 | 106/18723 | 9.81e-11 | 2.96e-09 | 81 |
| GO:000699713 | Esophagus | ESCC | nucleus organization | 96/8552 | 133/18723 | 4.66e-10 | 1.21e-08 | 96 |
| GO:2001020110 | Esophagus | ESCC | regulation of response to DNA damage stimulus | 145/8552 | 219/18723 | 5.97e-10 | 1.50e-08 | 145 |
| GO:000700418 | Esophagus | ESCC | telomere maintenance via telomerase | 56/8552 | 69/18723 | 1.40e-09 | 3.30e-08 | 56 |
| GO:003450211 | Esophagus | ESCC | protein localization to chromosome | 70/8552 | 92/18723 | 2.54e-09 | 5.64e-08 | 70 |
| GO:001083319 | Esophagus | ESCC | telomere maintenance via telomere lengthening | 61/8552 | 81/18723 | 5.24e-08 | 9.37e-07 | 61 |
| GO:005197217 | Esophagus | ESCC | regulation of telomerase activity | 39/8552 | 47/18723 | 1.48e-07 | 2.35e-06 | 39 |
| GO:005197318 | Esophagus | ESCC | positive regulation of telomerase activity | 30/8552 | 34/18723 | 2.73e-07 | 4.02e-06 | 30 |
| GO:000627816 | Esophagus | ESCC | RNA-dependent DNA biosynthetic process | 56/8552 | 75/18723 | 3.03e-07 | 4.30e-06 | 56 |
| GO:00063024 | Esophagus | ESCC | double-strand break repair | 152/8552 | 251/18723 | 1.33e-06 | 1.62e-05 | 152 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WRAP53 | SNV | Missense_Mutation | c.1399G>C | p.Val467Leu | p.V467L | Q9BUR4 | protein_coding | deleterious(0.03) | benign(0.158) | TCGA-AO-A12F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | |
| WRAP53 | SNV | Missense_Mutation | c.1357N>T | p.Pro453Ser | p.P453S | Q9BUR4 | protein_coding | tolerated(0.26) | possibly_damaging(0.556) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| WRAP53 | insertion | Frame_Shift_Ins | novel | c.424_425insAGGACCCAGCTCCAGCCCATCCTTCTCCCCACGCTTCCCCGAT | p.Gly142GlufsTer42 | p.G142Efs*42 | Q9BUR4 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| WRAP53 | deletion | Frame_Shift_Del | novel | c.690delC | p.Trp231GlyfsTer4 | p.W231Gfs*4 | Q9BUR4 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| WRAP53 | SNV | Missense_Mutation | c.259N>G | p.Ser87Gly | p.S87G | Q9BUR4 | protein_coding | tolerated_low_confidence(0.39) | benign(0) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| WRAP53 | SNV | Missense_Mutation | rs759563684 | c.1246C>T | p.Arg416Cys | p.R416C | Q9BUR4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AZ-5407-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| WRAP53 | SNV | Missense_Mutation | rs773992093 | c.349N>A | p.Glu117Lys | p.E117K | Q9BUR4 | protein_coding | tolerated(0.13) | benign(0.078) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| WRAP53 | deletion | Frame_Shift_Del | novel | c.207delN | p.Asp71ThrfsTer19 | p.D71Tfs*19 | Q9BUR4 | protein_coding | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| WRAP53 | deletion | Frame_Shift_Del | novel | c.226delN | p.Ser76ProfsTer14 | p.S76Pfs*14 | Q9BUR4 | protein_coding | TCGA-AG-A023-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| WRAP53 | SNV | Missense_Mutation | novel | c.529N>G | p.Trp177Gly | p.W177G | Q9BUR4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |